Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 1/20 | 0.32 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
| ▸ | MTOR | P42345 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.30 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.30 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4868692 | 0.90 | PTGS2 (0.35) | MTORMAPK14PTGS2AVPR1BBRD4 | |
| SCHEMBL2995091 | 0.81 | MAPK1 (0.41) | ALDH1A1BRD4 | |
| SCHEMBL4875229 | 0.81 | KCNH2 (0.36) | PTGS2BRD4CREBBP | |
| SCHEMBL5227324 | 0.78 | HRH1 (0.37) | SMOHRH1MTORALDH1A1HIF1A | |
| SCHEMBL4866906 | 0.77 | KCNH2 (0.38) | SMOPTGS2BRD4CREBBP | |
| SCHEMBL4868332 | 0.77 | ALDH1A1 (0.37) | SMOHRH1ALDH1A1 | |
| SCHEMBL4875039 | 0.76 | KCNH2 (0.38) | HRH1MTORBRD4CREBBP | |
| SCHEMBL3931763 | 0.76 | GRIN2B (0.39) | SMOHRH1MTORALDH1A1HIF1A | |
| SCHEMBL4875667 | 0.75 | SMO (0.33) | SMOHRH1ALDH1A1 | |
| SCHEMBL4876035 | 0.75 | GRIN2B (0.39) | SMOHRH1MTORBRD4CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051384-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. | 2008-02-28 | — | — | US | disclosed |
| US-20080051384-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. | 2008-02-28 | — | — | US | disclosed |
| US-20080051384-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051384-A1 | ANTIVIRAL AGENTS | EIF2AK2, MAVS, ZC3HAV1 | SMO 4550/4885HRH1 3900/4885MTOR 1386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.